Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
|Videos|July 14, 2016
The Optimal Use of Identifying Genetic Risk Factors in Prostate Cancer
Author(s)Fred Schumacher, PhD, MPH
Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that highlights the optimal use of the identification of genetic risk factors in prostate cancer, as well as the biology of developing prostate cancer.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
5